CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

The phase III CheckMate 77T trial has validated that the use of perioperative nivolumab does not adversely affect health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with advanced stage III N2 disease. Presented at the International Association for the Study of Lung Cancer conference, the study measured HRQoL through patient-reported outcomes during and after treatment. Results indicate that nivolumab enhanced both survival and overall patient well-being, particularly beneficial for high-risk patients undergoing surgery.